APPLICATION
ANDA206197
TYPE
ANDA
ORIGINAL APPROVAL
2016-06-09
LATEST ACTION
2023-08-29
ROUTE
INTRAVENOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Prescription
Products
FOSAPREPITANT DIMEGLUMINEPrescription
FOSAPREPITANT DIMEGLUMINE EQ 150MG BASE/VIAL · POWDER · INTRAVENOUS
Approval history
2023-08-29Labeling · Supplement 8 · standardAP
2021-01-06Labeling · Supplement 1 · standardAP
2021-01-06Labeling · Supplement 4 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.